Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 22, Number 3—March 2016

Online Report

Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis

Jennifer FurinComments to Author , Grania Brigden, Erica Lessem, Michael Rich, Laura Vaughan, and Sharonann Lynch
Author affiliations: Harvard Medical School, Boston, Massachusettes, USA (J. Furin); Médecins Sans Frontières Access Campaign, Geneva, Switzerland (G. Brigden, S. Lynch); Treatment Action Group, New York, NY, USA (E. Lessem); Brigham and Women’s Hospital, Boston (M. Rich); Partners In Health, Boston (M. Rich, L. Vaughan)

Main Article

Figure 1

Global progress on programmatic use of bedaquiline (BDQ) to treat multidrug-resistant tuberculosis. Blue indicates countries using BDQ under program conditions. Green indicates countries awaiting arrival of BDQ to use it under program conditions. Gray indicates countries that have not reported using BDQ under program conditions.

Figure 1. Global progress on programmatic use of bedaquiline (BDQ) to treat multidrug-resistant tuberculosis. Blue indicates countries using BDQ under program conditions. Green indicates countries awaiting arrival of BDQ to use it under program conditions. Gray indicates countries that have not reported using BDQ under program conditions.

Main Article

Page created: February 18, 2016
Page updated: February 18, 2016
Page reviewed: February 18, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external